Evidence Files

Zinc for Colds: Why Most Lozenges on the Shelf Are the Wrong Dose

Q: Are there downsides?

Yes, and Cochrane records them: an increase in non-serious adverse events — mainly bad taste and nausea, which at lozenge doses is common enough to make people stop. Separately, intranasal zinc products were withdrawn after being linked to lasting loss of smell. Oral lozenges are a different risk profile from nasal sprays, but "zinc is a mineral so it must be harmless" isn't the right frame.

In 2024, Cochrane pooled 34 trials and 8,526 participants and delivered a shrug: zinc doesn't prevent colds, and its effect on duration is real but modest. What that headline number hides is a decade-old finding that most zinc products on pharmacy shelves were never dosed to work in the first place — and a live methodological fight over whether Cochrane's own math undersold the drug that does.

Published: 27 August 2026

Verdict

TREATMENT (partially confirmed)

We searched PubMed and Cochrane Library for zinc and the common cold. The 2024 Cochrane review (Nault et al., 34 trials, 8,526 participants) found essentially no prevention effect — cold incidence barely moved (RR 0.93, low-certainty evidence) even with months of daily supplementation. For treatment, started after symptoms begin, zinc cut cold duration by roughly 2.4 days on average — but the review rated that evidence low-certainty too, partly because it pooled wildly different doses and delivery methods into one number. Separate dose-response analyses going back to 2011 tell a sharper story: trials using less than 75mg of elemental zinc a day found no benefit at all; trials at 75-92mg/day, specifically as zinc acetate, found colds cut by roughly a third.

Why Europe keeps buying it every winter

Zinc's cold-fighting reputation is older than vitamin C's modern one and rests on a real biological mechanism, not folklore: zinc ions can interfere with rhinovirus replication and with the intercellular adhesion molecule the virus uses to enter nasal cells. That gave the claim a plausibility vitamin C never quite had, and pharmacy chains across the EU and UK built a genuine product category around it — lozenges, sprays, syrups, and daily tablets marketed as "immune support", sold alongside vitamin C every autumn.

The global market for zinc cold lozenges alone is now worth over a billion euros a year and growing at roughly 7% annually, with Europe as its second-largest region after North America. Pharmacies and drugstores handle the largest share of that — consumers trust the channel, and a pharmacist recommending zinc carries more weight than an influencer doing the same.

What most of that market doesn't advertise is that "zinc" isn't one product. It's a mineral sold in at least four different chemical salts, three delivery routes, and doses that vary more than tenfold between brands — and the clinical trial record shows that these differences are not cosmetic. They're the difference between a real effect and a placebo.

What the science actually says

Prevention doesn't work. The 2024 Cochrane review pooled 34 trials and 8,526 participants and concluded that zinc may have little or no effect on preventing colds. The risk ratio was 0.93 (95% CI 0.85 to 1.01), rated low-certainty evidence — months of daily supplementation for no measurable change in whether you get sick.
Treatment has a real but conditional effect. The same review found zinc may reduce the duration of a cold already underway — alongside an increase in non-serious adverse events. Cochrane rated the certainty low here too, citing wide variation between studies in dose, salt and delivery route, plus incomplete reporting.
Dose is the variable nobody puts on the front of the label. An individual patient data meta-analysis of high-dose zinc acetate lozenge trials found colds shortened by 2.73 to 2.94 days against a seven-day average — roughly a third. That effect was not modified by allergy status, smoking, baseline severity, age, sex or ethnicity, which is unusually consistent. Most consumer "immune support" tablets at 10–25 mg a day are nowhere near the doses tested.
The salt matters as much as the dose. Analyses of high-dose zinc acetate lozenges report effects on individual cold symptoms that gluconate formulations have not matched. The reason is chemical rather than commercial: some gluconate lozenges are flavoured with citric acid, which binds free zinc ions in saliva so tightly that little active zinc reaches throat tissue — a formulation flaw, not a dosing one.
The pooling problem is why the two literatures disagree. Cochrane's headline number averages together interventions that differ enormously in dose, salt and route — lozenges and nasal sprays, gram-scale and milligram-scale doses. The acetate-specific analyses, which compare like with like, find a much larger and more consistent effect. Both can be right: they are answering different questions.
The nasal route is a separate story, and a cautionary one. Intranasal zinc products were pulled from the market after regulators linked them to zinc-induced anosmia — permanent or long-lasting loss of smell. It's a reminder that "zinc" spans genuinely different risk profiles depending on how it's delivered, which is also why pooling nasal and oral trials together is questionable science.

What the label claims vs. what the evidence shows

Common marketing claims

"Supports your immune system." "Helps fight off colds." Sold as a daily 10-25mg tablet for general immunity, or as an acute lozenge "at the first sign of a cold" — rarely with any indication of elemental zinc content, salt form, or how the dose compares to what was actually tested in trials.

What the evidence shows

No meaningful prevention effect at any dose tested. A real, moderate treatment effect — but only starting after symptoms begin, only at the high doses used in the acetate lozenge trials, and most consistently with zinc acetate rather than gluconate. A daily 15 mg "immune support" tablet is testing a different drug, at a different dose, for a different use case than the trials that show a benefit.

Frequently asked questions

Does taking zinc daily stop me catching colds?

No. Cochrane's 2024 review of 34 trials and 8,526 participants concluded that zinc may have little or no effect on preventing colds, with a risk ratio of 0.93 whose confidence interval crosses 1. Months of daily supplementation did not measurably change how often people got sick. This is the use case almost every "immune support" product on the shelf is sold for.

So when does zinc actually work?

Started after symptoms begin, at high doses, in the right chemical form. The individual patient data meta-analysis of zinc acetate lozenge trials found colds shortened by 2.73 to 2.94 days against a seven-day average — roughly a third — and the effect held consistently across allergy status, smoking, age, sex and severity. That is a specific intervention, not a general mineral top-up.

How do I tell whether a product matches what was tested?

Look for three things on the back of the pack, not the front: the elemental zinc content per lozenge, the salt (acetate rather than gluconate), and whether it's a lozenge meant to dissolve slowly in the mouth rather than a tablet to swallow. Products that don't state elemental content are, in practice, not comparable to the trial evidence at all.

Are there downsides?

Yes, and Cochrane records them: an increase in non-serious adverse events — mainly bad taste and nausea, which at lozenge doses is common enough to make people stop. Separately, intranasal zinc products were withdrawn after being linked to lasting loss of smell. Oral lozenges are a different risk profile from nasal sprays, but "zinc is a mineral so it must be harmless" isn't the right frame.

Should I take zinc for a cold, then?

It's a reasonable thing to try if you start early, use the right form and dose, and accept that the taste is unpleasant — the evidence for shortening an existing cold is among the better evidence in this section. What isn't supported is taking a low-dose zinc tablet daily through winter hoping not to get ill. Those are two different products doing two different things, and only one of them has a trial behind it.

Our Conclusion

Zinc for colds is a rarer case in supplement science: the effect is real, mechanistically plausible, and shows up consistently in the trials that used the right form and dose — which makes it more defensible than most of what shares a shelf with it. But "zinc works" is doing a lot of unearned work on packaging that doesn't specify salt, dose, or timing. If you're buying it to prevent colds, the evidence says don't bother. If you're buying it to shorten one that's already started, look past the front label for elemental zinc content and salt form — zinc acetate, upwards of 75mg a day, started within 24 hours of symptoms — because the trials that found nothing were usually testing a lozenge that was never going to work at the dose it was sold at.

Sources

Every claim in this article rests on a primary publication. Links go to the publisher's site or to PubMed, the US National Library of Medicine database.

This article is for informational purposes only and does not constitute medical advice. Trick or Treatment analyses the presence of clinical studies in open scientific databases — PubMed and Cochrane Library. The absence of studies in these databases does not automatically mean a drug is ineffective, but it does mean its effectiveness has not been confirmed by evidence-based medicine standards. Any treatment decisions should be made together with your doctor.